522 related articles for article (PubMed ID: 28069878)
1. MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.
Li P; Zhang X; Wang H; Wang L; Liu T; Du L; Yang Y; Wang C
Mol Cancer Ther; 2017 Apr; 16(4):739-751. PubMed ID: 28069878
[TBL] [Abstract][Full Text] [Related]
2. MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.
Huo Y; Li Q; Wang X; Jiao X; Zheng J; Li Z; Pan X
Oncotarget; 2017 Jul; 8(29):46993-47006. PubMed ID: 28388584
[TBL] [Abstract][Full Text] [Related]
3. Chronic oxymatrine treatment induces resistance and epithelial‑mesenchymal transition through targeting the long non-coding RNA MALAT1 in colorectal cancer cells.
Xiong Y; Wang J; Zhu H; Liu L; Jiang Y
Oncol Rep; 2018 Mar; 39(3):967-976. PubMed ID: 29328404
[TBL] [Abstract][Full Text] [Related]
4. LncRNA MALAT1 promotes colorectal cancer development by sponging miR-363-3p to regulate EZH2 expression.
Xie JJ; Li WH; Li X; Ye W; Shao CF
J Biol Regul Homeost Agents; 2019; 33(2):331-343. PubMed ID: 30972996
[TBL] [Abstract][Full Text] [Related]
5. Long Noncoding RNA XIST Regulates miR-137-EZH2 Axis to Promote Tumor Metastasis in Colorectal Cancer.
Liu X; Cui L; Hua D
Oncol Res; 2018 Dec; 27(1):99-106. PubMed ID: 29495975
[TBL] [Abstract][Full Text] [Related]
6. Posttranscriptional silencing of the lncRNA MALAT1 by miR-217 inhibits the epithelial-mesenchymal transition via enhancer of zeste homolog 2 in the malignant transformation of HBE cells induced by cigarette smoke extract.
Lu L; Luo F; Liu Y; Liu X; Shi L; Lu X; Liu Q
Toxicol Appl Pharmacol; 2015 Dec; 289(2):276-85. PubMed ID: 26415832
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA-22/Snail family transcriptional repressor 1 axis.
Chen S; Wang G; Tao K; Cai K; Wu K; Ye L; Bai J; Yin Y; Wang J; Shuai X; Gao J; Pu J; Li H
Cancer Sci; 2020 May; 111(5):1582-1595. PubMed ID: 32129914
[TBL] [Abstract][Full Text] [Related]
8. LncRNA MALAT1 promotes epithelial-to-mesenchymal transition of esophageal cancer through Ezh2-Notch1 signaling pathway.
Chen M; Xia Z; Chen C; Hu W; Yuan Y
Anticancer Drugs; 2018 Sep; 29(8):767-773. PubMed ID: 29916899
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA ZNFX1-AS1 promotes the tumor progression and metastasis of colorectal cancer by acting as a competing endogenous RNA of miR-144 to regulate EZH2 expression.
Shi L; Hong X; Ba L; He X; Xiong Y; Ding Q; Yang S; Peng G
Cell Death Dis; 2019 Feb; 10(3):150. PubMed ID: 30770796
[TBL] [Abstract][Full Text] [Related]
10. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis.
Li L; Shang J; Zhang Y; Liu S; Peng Y; Zhou Z; Pan H; Wang X; Chen L; Zhao Q
Oncol Rep; 2017 Sep; 38(3):1383-1392. PubMed ID: 28731151
[TBL] [Abstract][Full Text] [Related]
11. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling.
Shi CJ; Xue ZH; Zeng WQ; Deng LQ; Pang FX; Zhang FW; Fu WM; Zhang JF
Cancer Gene Ther; 2023 Jun; 30(6):855-865. PubMed ID: 36782047
[TBL] [Abstract][Full Text] [Related]
12. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
[TBL] [Abstract][Full Text] [Related]
13. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
14. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
15. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205.
Hirata H; Hinoda Y; Shahryari V; Deng G; Nakajima K; Tabatabai ZL; Ishii N; Dahiya R
Cancer Res; 2015 Apr; 75(7):1322-31. PubMed ID: 25600645
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
17. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.
Wang X; Sehgal L; Jain N; Khashab T; Mathur R; Samaniego F
J Transl Med; 2016 Dec; 14(1):346. PubMed ID: 27998273
[TBL] [Abstract][Full Text] [Related]
18. TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p.
Cao J; Han X; Qi X; Jin X; Li X
Int J Oncol; 2017 Oct; 51(4):1115-1123. PubMed ID: 28902349
[TBL] [Abstract][Full Text] [Related]
19. TGF-β-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12.
Fan Y; Shen B; Tan M; Mu X; Qin Y; Zhang F; Liu Y
Clin Cancer Res; 2014 Mar; 20(6):1531-41. PubMed ID: 24449823
[TBL] [Abstract][Full Text] [Related]
20. The Lncrna-TUG1/EZH2 Axis Promotes Pancreatic Cancer Cell Proliferation, Migration and EMT Phenotype Formation Through Sponging Mir-382.
Zhao L; Sun H; Kong H; Chen Z; Chen B; Zhou M
Cell Physiol Biochem; 2017; 42(6):2145-2158. PubMed ID: 28813705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
